Please login to the form below

Not currently logged in
Email:
Password:

lacosamide

This page shows the latest lacosamide news and features for those working in and with pharma, biotech and healthcare.

Tecentriq’s triple negative breast cancer use among key CHMP nods

Tecentriq’s triple negative breast cancer use among key CHMP nods

UCB’s Vimpat (lacosamide) also gained a thumbs up in the epilepsy market, with a recommendation in partial-onset seizures with or without secondary generalisation.

Latest news

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics